<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522326</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002837</org_study_id>
    <nct_id>NCT01522326</nct_id>
  </id_info>
  <brief_title>Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness</brief_title>
  <official_title>Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy of metoclopramide in relieving the
      symptoms of Acute Mountain Sickness (AMS).

      It is our hypothesis that the combined antiemetic and analgesic effects of metoclopramide
      (which has been study-proven to be effective in relieving symptoms of migraine headache) will
      prove to be more efficacious in relieving symptoms of acute mountain sickness than the
      standard, previously-studied analgesic medication, ibuprofen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute Mountain Sickness (AMS) is a well described disease process that occurs as a result of
      rapid exposure to high altitude. High altitude headache (HAH) is defined as the presence of
      headache in the setting of a recent increase in altitude. When HAH is associated with nausea,
      vomiting, fatigue, weakness, dizziness, lightheadedness or poor sleeping, AMS is diagnosed.
      While benign, AMS is very common, afflicting up to 80 % of travelers who ascend rapidly to
      14,000 ft, and can be debilitating. AMS is thought to occur secondary to hypoxia-induced
      cerebral vasodilation. The antiemetic metoclopramide has been well studied and is commonly
      administered for treatment of migraine headaches in emergency departments across the U.S. The
      symptoms of migraine headaches are often similar to those of AMS. The mechanism of
      metoclopramide‟s beneficial effect in this indication appear to be a result of its antagonism
      of central and peripheral dopamine receptors,most notably by blocking stimulation of the
      medullary chemoreceptor trigger zone. No studies have yet evaluated the potential benefits of
      metoclopramide for the relief of AMS. In contrast, ibuprofen has been well studied and found
      to be an effective treatment for the relief of symptoms of high altitude headache and AMS.

      The study will be a convenience sample of trekkers traveling through the Annapurna Circuit in
      Nepal during the 3 month time period of March-May, 2012. Subjects will be recruited from
      visitors to Manang, Nepal staying in local hostels, those visiting the Himalayan Rescue
      Association clinic in Manang, and those responding to locally posted signage regarding study
      enrollment.

      Eligible patients will be consented and enrolled in the study. Patients will be randomized to
      receive either Ibuprofen 400mg or Metoclopramide 10mg by mouth. Investigators will be blinded
      as to which arm of the study the patient is enrolled. Participants will be assessed by Lake
      Louise Score and Visual Analog Scale for headache and nausea severity immediately prior to
      ingestion of study medication, and then serially at 30, 60, and 120 minutes following
      medication ingestion. Standard statistical analysis of the Lake Louise AMS scores and visual
      analog scales will be used to determine which medication is more effective in treating acute
      mountain sickness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache and Nausea Visual Analog Scales</measure>
    <time_frame>120 minutes</time_frame>
    <description>Subjects will complete 100mm visual analog scales of both headache and nausea at time zero, 30, 60, and 120 minutes after taking the study medication. Visual analog scales are a valid assessment of symptom severity for acute mountain sickness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lake Louise Acute Mountain Sickness Score</measure>
    <time_frame>120 minutes</time_frame>
    <description>Subjects will take the Lake Louise Acute Mountains Sickness score before taking the medication and 120 minutes after taking the medication. The Lake Louise Acute Mountain Sickness Score is a standard measure of the severity of acute mountain sickness and is commonly used in studies involving acute mountain sickness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Mountain Sickness</condition>
  <condition>High Altitude Headache</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 400mg tablet. Take one dose by mouth.</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Advil</other_name>
    <other_name>Motrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 10mg tablet. Take one tablet by mouth.</description>
    <arm_group_label>Metoclopramide</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence at Manang recruitment center (at approximately 11,500 ft) during the dates
             March through May, 2012.

          -  Recent increase in altitude of &gt; 1000 ft vertical in last 24 hours

          -  Presence of headache and at least one other symptom required for diagnosis of acute
             mountain sickness (including nausea, vomiting, fatigue, weakness, dizziness,
             lightheadedness or poor sleeping.)

        Exclusion Criteria:

          -  Age less than 19 years old

          -  Known allergy or contraindication to either ibuprofen or metoclopramide

          -  Evidence of severe high altitude illness (e.g. High altitude pulmonary edema (HAPE) as
             evidenced by dyspnea at rest -- or of High Altitude Cerebral Edema (HACE) as evidenced
             by altered mental status or ataxia)

          -  Known or suspected pregnancy

          -  Use of other analgesic or antiemetic within 8 hours of study enrollment

          -  History of migraines or other chronic headache disorders

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman S Harris, MD, MFA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John B Tanner, MD</last_name>
    <phone>206-661-1143</phone>
    <email>JBTANNER@PARTNERS.ORG</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manang Clinic of the Himalayan Rescue Association</name>
      <address>
        <city>Manang</city>
        <state>District of Manang</state>
        <zip>33500</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John B Tanner, MD</last_name>
      <phone>206-661-1143</phone>
      <email>JBTANNER@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>John B Tanner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <reference>
    <citation>Roach RC, Bartsch P, Hackett PH, Oelz O. The Lake Louise acute mountain sickness scoring system. Hypoxia and Molecular Medicine, J.R. Sutton, C. S. Huston, and G. Coates eds. Burlinton, VT, USA: Queen City Printers; 1993.</citation>
  </reference>
  <reference>
    <citation>Gilbert DL. The first documented report of mountain sickness: the China or Headache Mountain story. Respir Physiol. 1983 Jun;52(3):315-26.</citation>
    <PMID>6351209</PMID>
  </reference>
  <reference>
    <citation>Gilbert DL. The first documented description of mountain sickness: the Andean or Pariacaca story. Respir Physiol. 1983 Jun;52(3):327-47.</citation>
    <PMID>6351210</PMID>
  </reference>
  <reference>
    <citation>Hultgren HN. High Altitude Pulmonary Edema. High Altitude Medicine. Stanford, CA: Hultgren Publications; 1997.</citation>
  </reference>
  <reference>
    <citation>Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA. 1989 Feb 3;261(5):732-4.</citation>
    <PMID>2911169</PMID>
  </reference>
  <reference>
    <citation>Maggiorini M, Bühler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990 Oct 13;301(6756):853-5.</citation>
    <PMID>2282425</PMID>
  </reference>
  <reference>
    <citation>Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc. 2002 Dec;34(12):1886-91.</citation>
    <PMID>12471292</PMID>
  </reference>
  <reference>
    <citation>Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001 Jul 12;345(2):107-14. Review.</citation>
    <PMID>11450659</PMID>
  </reference>
  <reference>
    <citation>Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med. 1991 Mar;154(3):289-93.</citation>
    <PMID>2028586</PMID>
  </reference>
  <reference>
    <citation>Zell SC, Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med. 1988 May;148(5):541-5.</citation>
    <PMID>3051673</PMID>
  </reference>
  <reference>
    <citation>Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976 Nov 27;2(7996):1149-55.</citation>
    <PMID>62991</PMID>
  </reference>
  <reference>
    <citation>Broome JR, Stoneham MD, Beeley JM, Milledge JS, Hughes AS. High altitude headache: treatment with ibuprofen. Aviat Space Environ Med. 1994 Jan;65(1):19-20.</citation>
    <PMID>8117220</PMID>
  </reference>
  <reference>
    <citation>Gertsch JH, Lipman GS, Holck PS, Merritt A, Mulcahy A, Fisher RS, Basnyat B, Allison E, Hanzelka K, Hazan A, Meyers Z, Odegaard J, Pook B, Thompson M, Slomovic B, Wahlberg H, Wilshaw V, Weiss EA, Zafren K. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med. 2010 Sep;21(3):236-43. doi: 10.1016/j.wem.2010.06.009. Epub 2010 Jun 16.</citation>
    <PMID>20832701</PMID>
  </reference>
  <reference>
    <citation>Harris NS, Wenzel RP, Thomas SH. High altitude headache: efficacy of acetaminophen vs. ibuprofen in a randomized, controlled trial. J Emerg Med. 2003 May;24(4):383-7.</citation>
    <PMID>12745039</PMID>
  </reference>
  <reference>
    <citation>Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008041. doi: 10.1002/14651858.CD008041.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;(4):CD008041.</citation>
    <PMID>20393963</PMID>
  </reference>
  <reference>
    <citation>Griffith JD, Mycyk MB, Kyriacou DN. Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. J Pain. 2008 Jan;9(1):88-94. Epub 2007 Nov 5.</citation>
    <PMID>17981511</PMID>
  </reference>
  <reference>
    <citation>Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, Gallagher EJ. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005 Feb 8;64(3):463-8.</citation>
    <PMID>15699376</PMID>
  </reference>
  <reference>
    <citation>Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004 Dec 11;329(7479):1369-73. Epub 2004 Nov 18.</citation>
    <PMID>15550401</PMID>
  </reference>
  <reference>
    <citation>The Lake Louise Consensus on the Definition and Quantification of Altitude Illness. In: Sutton J, Coates G, Houston C, eds. Hypoxia and Molecular Medicine. Burlington, VT: Queen City Printers; 1993.</citation>
  </reference>
  <reference>
    <citation>Kayser B, Aliverti A, Pellegrino R, Dellaca R, Quaranta M, Pompilio P, Miserocchi G, Cogo A. Comparison of a visual analogue scale and Lake Louise symptom scores for acute mountain sickness. High Alt Med Biol. 2010 Spring;11(1):69-72. doi: 10.1089/ham.2009.1046.</citation>
    <PMID>20367491</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>N. Stuart Harris MD MFA</investigator_full_name>
    <investigator_title>Director, MGH Wilderness Medicine Fellowship; Chief, Division of Wilderness Medicine, Department of Emergency Medicine, Massachusetts General Hospital; Assistant Professor of Surgery, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Acute Mountain Sickness</keyword>
  <keyword>High Altitude Headache</keyword>
  <keyword>Lake Louise AMS Score</keyword>
  <keyword>Visual Analog Scale</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Metoclopramide</keyword>
  <keyword>Nepal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

